Complete remission best for tapering SLE treatment
To prevent systemic lupus erythematosus flare, tapering of corticosteroid or immunosuppressive therapy is best done when patients are in complete remission and have maintained stable disease for at least 6 months, say researchers.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Add-on tofacitinib shows treatment promise in SSc-ILD
The addition of tofacitinib to conventional disease-modifying antirheumatic drugs could help alleviate sclerosis in patients with systemic sclerosis-associated interstitial lung disease, suggests research.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Autoantibodies may identify Sjögren’s syndrome in Ro-negative patients
The use of autoantibody biomarkers could be a feasible way of identifying Sjögren’s syndrome in patients lacking the anti-Ro antibody without the need for a salivary gland lip biopsy, suggests a proof-of-concept study.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Serious infection risk not increased by rituximab and belimumab in SLE
Neither rituximab nor belimumab significantly increase the risk for serious infection in patients with systemic lupus erythematosus compared with the standard of care, researchers report.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Baricitinib disappoints in SLE-BRAVE trials
Baricitinib has achieved largely negative results in the SLE-BRAVE trials, published in The Lancet.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Reflux symptoms predict interstitial lung disease progression in SSc
Post-hoc analysis of a randomised trial shows that the severity of reflux symptoms in patients with systemic sclerosis predicts radiographic progression of interstitial lung disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Anti-dsDNA antibodies could predict response to B cell-targeted therapies in SLE
IgA2 anti-dsDNA antibodies may represent a biomarker of response to B cell-targeted therapies in patients with systemic lupus erythematosus, suggest study findings from Michael Ehrenstein and colleagues.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Research identifies sex differences in SSc-ILD outcomes
Men with systemic sclerosis-associated interstitial lung disease may have a more severe disease course than women, whereas women with the condition could be more likely to experience certain adverse events when treated with immunosuppressive therapy, suggest findings from two studies.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Prophylactic antivirals may help prevent symptomatic COVID-19 in rituximab-treated patients
Pre-exposure prophylaxis with tixagevimab and cilgavimab may be an effective strategy to prevent symptomatic SARS-CoV-2 infection among people with rheumatic diseases treated with rituximab, suggest findings from a real-world study.
Support for JAK inhibitors as ‘drug of choice’ for patients with PsA and significant joint disease
JAK inhibitors show promise for the treatment of moderate-to-severe psoriasis and psoriatic arthritis, finds a systematic review and meta-analysis of more than 6000 patients.
